CJC-1295 vs MK-677
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: CJC-1295 DAC, CJC-1295 no DAC
A synthetic analog of growth hormone-releasing hormone (GHRH) that stimulates GH release from the pituitary. Often combined with a GHRP like Ipamorelin for synergistic effects.
Also: Ibutamoren, Nutrobal
An orally active growth hormone secretagogue that mimics ghrelin. Although technically not a peptide, it is frequently discussed alongside GH peptides due to similar effects.
Key Comparison Insights
- Both peptides belong to the Growth Hormone category, suggesting similar primary applications.
Detailed Comparison
| Attribute | CJC-1295 | MK-677 |
|---|---|---|
| Category | Growth Hormone | Growth Hormone |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | CJC-1295 binds to GHRH receptors on the pituitary, stimulating GH synthesis and release. The DAC (Drug Affinity Complex) version binds to albumin, extending half-life to 6-8 days. Without DAC (Mod GRF 1-29), half-life is about 30 minutes. | MK-677 binds to ghrelin receptors (GHSR) in the brain, stimulating sustained GH release and increasing IGF-1 levels. Unlike injectable GHRPs, it is orally bioavailable and has a long half-life providing 24-hour GH elevation. |
| Common Dosing | 100 mcg daily (no DAC) or 2 mg weekly (with DAC) Daily (no DAC) or 1-2x weekly (with DAC) | 10-25 mg daily Once daily, often before bed |
| Administration | Subcutaneous injection | Oral |
| Typical Duration | 8-12 weeks | 8-12 weeks or longer |
| Best Time to Take | Before bed | Before bed |
Possible Side Effects May vary by individual |
|
|
| Research Summary | Phase II trial in HIV lipodystrophy patients was discontinued after a patient death (MI, deemed unrelated but trial ended as precaution). Earlier studies show sustained 2-10 fold increase in GH and IGF-1 levels with good tolerability at doses up to 60 mcg/kg. | Studies show increases in GH and IGF-1 levels, improved sleep quality, and increased lean body mass. However, a clinical trial was stopped early due to heart failure concerns in elderly patients. FDA lists MK-677 as having significant safety risks. Never received FDA approval. |
Frequently Asked Questions: CJC-1295 vs MK-677
What is the difference between CJC-1295 and MK-677?
CJC-1295 is a growth hormone peptide that a synthetic analog of growth hormone-releasing hormone (ghrh) that stimulates gh release from the pituitary. often combined with a ghrp like ipamorelin for synergistic effects. MK-677 is a growth hormone peptide that an orally active growth hormone secretagogue that mimics ghrelin. although technically not a peptide, it is frequently discussed alongside gh peptides due to similar effects. The main differences lie in their mechanisms of action and clinical applications.
Which is better, CJC-1295 or MK-677?
Neither is universally "better" - the choice depends on your specific goals. CJC-1295 is typically used for growth hormone purposes, while MK-677 is used for growth hormone. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can CJC-1295 and MK-677 be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using CJC-1295 and MK-677 together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.
Related Comparisons
View Full Peptide Profiles
Educational Information Only
This comparison of CJC-1295 and MK-677 is for educational purposes only. Neither this comparison nor any information on this site constitutes medical advice. Always consult with qualified healthcare providers before making decisions about peptides or other substances.